Engineered Bacteria Deliver GLP-1 on Demand, Curbing Peptide-Degrading Gut Microbes in Mice

Scientists have engineered probiotic bacteria that release the appetite-regulating hormone glucagon-like peptide-1 (GLP-1) only when triggered by components of the diet, and in a mouse model of obesity this programmable delivery outperformed continuous microbial GLP-1 secretion at reducing both fat accumulation and fatty liver changes. The study, published open access in Genome Medicine, also uncovered a previously underappreciated obstacle to GLP-1-based therapies: certain gut bacteria carry genes encoding peptidase isoenzymes capable of degrading the hormone, and these GLP-1-inactivating taxa expanded specifically under persistent drug delivery. GLP-1 is an incretin hormone that governs energy homeostasis and is normally released after meals by enteroendocrine cells in the gut.

However, the authors note that such therapeutics are frequently associated with drug resistance and side effects, and that meal-linked, programmable GLP-1 delivery had rarely been explored. To address this gap, the team genetically engineered probiotic bacteria so that GLP-1 production is switched on by dietary cues, mimicking the hormone's natural postprandial release pattern rather than flooding the gut with a constant supply. The central aim of the study was to compare this diet-induced, programmable strategy against constitutive GLP-1 secretion from the same synthetic bacteria.

In the murine obesity model, the researchers directly evaluated the two delivery regimens side by side. The diet-induced approach produced greater anti-adiposity and anti-steatosis effects than persistent GLP-1 secretion, indicating that timing GLP-1 exposure to food intake, rather than maintaining uniformly elevated levels, may improve the metabolic benefit of microbial peptide delivery in this experimental setting. By profiling the gut bacterial communities of treated mice, the team discovered genes encoding microbe-derived GLP-1 peptidase isoenzymes in gut bacteria that were specifically enriched under persistent GLP-1 delivery.

According to the study, these GLP-1-inactivation-capable taxa were also observed in murine and clinical studies, suggesting that the enrichment is not confined to the engineered-bacteria model alone. In contrast, the diet-induced delivery strategy minimized the abundance of these bacteria, leaving less microbial capacity to break down the therapeutic peptide. The authors characterize the gut microbiome not as a passive backdrop for peptide therapy but as an active participant that can shape drug effectiveness through enzymes that degrade the hormone.

The conclusions highlight host-microbiome-therapeutic interactions as a key consideration for peptide-based medicines and argue for programmable delivery strategies that anticipate, rather than ignore, the microbial enzymes capable of degrading them. Within the scope of this study, matching the delivery pattern of a gut hormone to its physiological rhythm was associated with both enhanced therapeutic effect and reduced expansion of gut microbes carrying GLP-1-degrading enzymes. Because the efficacy results come from a murine model of obesity, the findings cannot yet be read as demonstrated clinical benefits for patients, and the engineered bacteria themselves remain investigational.

The study establishes, in this animal model, a concrete design principle for peptide therapeutics: delivery patterns that mirror natural hormonal rhythms may work with, rather than against, the ecology of the gut.

Subject of Research: Diet-triggered synthetic bacteria for programmable GLP-1 delivery and gut microbial GLP-1 degradation in obesity

Article Title: Diet-induced programmable GLP-1 delivery by synthetic bacteria enhances anti-obesity efficacy with reduced gut bacterial taxa harboring GLP-1 inactivation potential

Article References: Wang, S., Zhang, B., He, Z., Si, J., Liu, S., Wang, Z., Zhang, S., Chen, J., Liang, X.-J., & Yang, Y. (2026). Diet-induced programmable GLP-1 delivery by synthetic bacteria enhances anti-obesity efficacy with reduced gut bacterial taxa harboring GLP-1 inactivation potential. Genome Medicine. https://doi.org/10.1186/s13073-026-01809-5

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01809-5

Keywords: GLP-1, synthetic biology, probiotics, obesity, gut microbiome, peptidases, programmable drug delivery, steatosis, enteroendocrine cells, Genome Medicine, mouse model, metabolic disease